| Dr Samina Aftab Choudhry, MD | |
|
310 Kennestone Hospital Blvd, Marietta, GA 30060-1120 | |
| (770) 793-7899 | |
| (770) 793-7865 |
| Full Name | Dr Samina Aftab Choudhry |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 31 Years |
| Location | 310 Kennestone Hospital Blvd, Marietta, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467685800 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 253779 (New York) | Secondary |
| 207QH0002X | Family Medicine - Hospice And Palliative Medicine | 72239 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Piedmont Athens Regional Medical Center | Athens, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Piedmont Athens Hospitalist Physicians Llc | 6305196411 | 105 |
News Archive
PPD, Inc. today confirmed that Takeda Pharmaceutical Company Limited's new drug application for NESINA® (alogliptin), a highly selective DPP-4 inhibitor for the treatment of type 2 diabetes, was approved by the Japanese Ministry of Health, Labour and Welfare on April 16. PPD's compound partnering division collaborated with Takeda to develop this product.
ZELTIQ, a California-based developer of ground-breaking non-invasive fat reduction technology, today announces that it has raised $25 million in Series D funding. Aisling Capital led the round and was joined by returning investors Advanced Technology Ventures, Frazier Healthcare Ventures and Venrock. Since being formed in 2005, ZELTIQ has raised approximately $50 million.
DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. and a leading provider of kidney care services, is celebrating its more than 3,600 dietitians and social workers during March for their distinctive and important roles in patient care.
Psychosocial support in women with advanced or metastatic breast cancer (MBC) is as important as the need for disease- and treatment-related information, according to results of a survey presented here today at the 30th Annual San Antonio Breast Cancer Symposium.
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.
› Verified 6 days ago
| Entity Name | Athens Regional Specialty Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083939136 PECOS PAC ID: 8325162340 Enrollment ID: O20100827000645 |
News Archive
PPD, Inc. today confirmed that Takeda Pharmaceutical Company Limited's new drug application for NESINA® (alogliptin), a highly selective DPP-4 inhibitor for the treatment of type 2 diabetes, was approved by the Japanese Ministry of Health, Labour and Welfare on April 16. PPD's compound partnering division collaborated with Takeda to develop this product.
ZELTIQ, a California-based developer of ground-breaking non-invasive fat reduction technology, today announces that it has raised $25 million in Series D funding. Aisling Capital led the round and was joined by returning investors Advanced Technology Ventures, Frazier Healthcare Ventures and Venrock. Since being formed in 2005, ZELTIQ has raised approximately $50 million.
DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. and a leading provider of kidney care services, is celebrating its more than 3,600 dietitians and social workers during March for their distinctive and important roles in patient care.
Psychosocial support in women with advanced or metastatic breast cancer (MBC) is as important as the need for disease- and treatment-related information, according to results of a survey presented here today at the 30th Annual San Antonio Breast Cancer Symposium.
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.
› Verified 6 days ago
| Entity Name | Piedmont Athens Hospitalist Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578079000 PECOS PAC ID: 6305196411 Enrollment ID: O20180911003967 |
News Archive
PPD, Inc. today confirmed that Takeda Pharmaceutical Company Limited's new drug application for NESINA® (alogliptin), a highly selective DPP-4 inhibitor for the treatment of type 2 diabetes, was approved by the Japanese Ministry of Health, Labour and Welfare on April 16. PPD's compound partnering division collaborated with Takeda to develop this product.
ZELTIQ, a California-based developer of ground-breaking non-invasive fat reduction technology, today announces that it has raised $25 million in Series D funding. Aisling Capital led the round and was joined by returning investors Advanced Technology Ventures, Frazier Healthcare Ventures and Venrock. Since being formed in 2005, ZELTIQ has raised approximately $50 million.
DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. and a leading provider of kidney care services, is celebrating its more than 3,600 dietitians and social workers during March for their distinctive and important roles in patient care.
Psychosocial support in women with advanced or metastatic breast cancer (MBC) is as important as the need for disease- and treatment-related information, according to results of a survey presented here today at the 30th Annual San Antonio Breast Cancer Symposium.
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Samina Aftab Choudhry, MD 2727 Paces Ferry Road, Suite 1-1100, Atlanta, GA 30339 Ph: (470) 271-3421 | Dr Samina Aftab Choudhry, MD 310 Kennestone Hospital Blvd, Marietta, GA 30060-1120 Ph: (770) 793-7899 |
News Archive
PPD, Inc. today confirmed that Takeda Pharmaceutical Company Limited's new drug application for NESINA® (alogliptin), a highly selective DPP-4 inhibitor for the treatment of type 2 diabetes, was approved by the Japanese Ministry of Health, Labour and Welfare on April 16. PPD's compound partnering division collaborated with Takeda to develop this product.
ZELTIQ, a California-based developer of ground-breaking non-invasive fat reduction technology, today announces that it has raised $25 million in Series D funding. Aisling Capital led the round and was joined by returning investors Advanced Technology Ventures, Frazier Healthcare Ventures and Venrock. Since being formed in 2005, ZELTIQ has raised approximately $50 million.
DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. and a leading provider of kidney care services, is celebrating its more than 3,600 dietitians and social workers during March for their distinctive and important roles in patient care.
Psychosocial support in women with advanced or metastatic breast cancer (MBC) is as important as the need for disease- and treatment-related information, according to results of a survey presented here today at the 30th Annual San Antonio Breast Cancer Symposium.
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.
› Verified 6 days ago
Dr. Yen-i Grace Chen, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1010 Johnson Ferry Rd, Marietta, GA 30068 Phone: 770-579-7900 Fax: 770-579-7942 | |
Neety Patel, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3707 Largent Way Nw, Marietta, GA 30064 Phone: 678-581-5830 Fax: 678-581-5835 | |
Jamin Graham, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 677 Church St Ne, Marietta, GA 30060 Phone: 770-793-5000 | |
Dr. Philip Batista, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1010 Johnson Ferry Rd, Marietta, GA 30068 Phone: 770-579-7900 Fax: 770-579-7932 | |
Dr. Harvey David Braunfeld, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 299 Pat Mell Rd Se, Marietta, GA 30060 Phone: 770-432-5500 Fax: 770-431-8363 | |
William Edward Snell, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 880 Canton Rd Ne, Suite 300, Marietta, GA 30060 Phone: 770-590-0585 Fax: 770-428-4087 | |
Dr. Miles Eli Brett, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2520 Windy Hill Rd Se, Suite 301, Marietta, GA 30067 Phone: 770-952-1032 Fax: 770-952-8579 |